TY  - BOOK
AU  - Waksman, Ron
TI  - Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
SN  - 0735-1097
PY  - 2013///
KW  - *Adenosine Diphosphate/tu [Therapeutic Use]
KW  - *Angioplasty, Balloon, Coronary
KW  - *Hemorrhage/et [Etiology]
KW  - *Myocardial Ischemia/et [Etiology]
KW  - *Platelet Aggregation Inhibitors/tu [Therapeutic Use]
KW  - *Platelet Function Tests
KW  - *Purinergic P2Y Receptor Antagonists/tu [Therapeutic Use]
KW  - Acute Coronary Syndrome/th [Therapy]
KW  - Blood Platelets/de [Drug Effects]
KW  - Coronary Artery Disease/th [Therapy]
KW  - Coronary Thrombosis/et [Etiology]
KW  - Coronary Thrombosis/pc [Prevention & Control]
KW  - Humans
KW  - Receptors, Purinergic P2Y12/de [Drug Effects]
KW  - Risk Assessment
KW  - Risk Factors
KW  - Stents/ae [Adverse Effects]
KW  - MedStar Heart & Vascular Institute
KW  - Consensus Development Conference
KW  - Journal Article
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
N2  - Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy. Copyright  2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved
UR  - http://dx.doi.org/10.1016/j.jacc.2013.07.101
ER  -